Novo Nordisk is cutting prices for Ozempic and Wegovy for cash-paying customers. Hollie Adams/Reuters

Facing increased competition in the weight loss market and intense pressure from President Donald Trump , Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients.

The move is the latest step in drugmakers’ efforts to provide discounts to Americans willing to buy medications directly from them and forgo insurance. Also, it’s another way Novo Nordisk is seeking to fend off compounding pharmacies that are cutting into the manufacturer’s sales by offering less-expensive versions of the super-popular GLP-1 drugs.

Novo Nordisk is now offering the first two monthly doses of Wegovy and Ozempic for $199, with the discou

See Full Page